UNSPSC 51313120: Levocetirizine dihydrochloride

This classification denotes a histamine-1 receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SOD6A38AGA. European Medicines Agency schedules Levocetirizine dihydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20474. Levocetirizine dihydrochloride generally arises in the molecular formula C21H25CLN2O3.2CLH. The term 'levocetirizine dihydrochloride' is a United States Adopted Name designation.

Most nations, for tariff and trade purposes, schedule levocetirizine dihydrochloride under HS 29335995 and SITC 51576. As of Q4 2014, LEVOCETIRIZINE DIHYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Levocetirizine dihydrochloride bears US NLM identifiers UMLS ID C1311681 and NCI Concept Code C72814. SMILES: C1CCC(CC1)[C@H](C2CCC(CC2)CL)N3CCN(CC3)CCOCC(=O)O.CL.CL.

UNSPSC 51313120 Levocetirizine dihydrochloride is a Commodity code that classifies individual pharmaceutical products, yet the recent state and local opportunities tagged under it span a much broader scope — naloxone procurement, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals and OTC products. State and local health agencies, health departments, and cooperative purchasing alliances are the primary issuing bodies, with activity ranging from small county-level health initiatives to statewide multi-jurisdiction cooperative purchasing vehicles. The work being solicited includes annual procurement of finished pharmaceutical units for community health distribution, exploratory market intelligence gathering on alternative pharmacy benefit channels, and establishment of standing contracts with manufacturers to supply generic drugs and OTC items through authorized wholesale distributors to state and local government facilities. The scope reflects demand for direct supplier relationships, compliance with cGMP and Drug Supply Chain Security Act standards, and logistics management including quarterly or ongoing deliveries to specified health facilities.

Geographic activity centers on Florida and Texas, with broader multi-state reach through cooperative purchasing. Seminole County, Florida released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023 and a two-year initial term plus one-year renewal option. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a direct-to-manufacturer prescription program designed to improve efficiency outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, released an RFP on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline, requiring vendors to maintain relationships with three authorized wholesalers and comply with a 3 percent administrative fee structure. Awards under MMCAP extend across participating jurisdictions including Oregon through June 30, 2028.